IRVINE, Calif., Sept. 4, 2012 /PRNewswire/ -- This morning,
Allergan, Inc. (NYSE: AGN) will mark the opening of the company's
first large facility in the state of New
Jersey. Company leaders will be joined by federal, state and
local government officials, community leaders, physicians and
employees as they officially open Allergan's new Research and
Development (R&D) Center in Bridgewater, New Jersey.
"For more than 60 years, Allergan has built a proud history
based on two fundamental principles - scientific innovation and
focus on doctors and their patients," said David E.I. Pyott, Allergan's Chairman of the
Board, President and Chief Executive Officer. "We will continue to
increase our investment in R&D to fuel innovation and expect to
spend over $1 billion in 2013. Our
New Jersey clinical development
site will allow us to benefit from the expertise of the many
talented R&D professionals that reside in this state and, most
importantly, bring novel medical therapies to patients across the
world."
Allergan is a multi-specialty health care company, with
headquarters in California, a
presence in more than 100 countries and approximately 10,500
employees worldwide. The company originally opened a small office
in Bedminster, NJ, in 2008. The
new R&D Center, which will be specifically focused on clinical
development, is a significant expansion of the company's footprint
in New Jersey and is expected to
eventually house several hundred employees.
"Our aggressive efforts to promote economic growth and foster
job creation and investment in our state are delivering results for
New Jerseyans. Allergan is a world-class, innovative company that
is committing to our state and people with several hundred high
quality, research and development new jobs," said Lt. Governor
Kim Guadagno, who has led the
Christie Administration's successful efforts to attract life
science companies to New Jersey.
"Creating good paying, private sector jobs that are sustainable
over the long term is the number one priority of the Christie
Administration."
"I'm proud to join in celebrating this step forward for
New Jersey's thriving biotech and
health care community with the expansion of Allergan's operations
to this new R&D facility, and especially proud to celebrate the
hundreds of new, high-skill jobs it's bringing to New Jersey," said U.S. Senator Robert Menendez (D-NJ), a long-time supporter of
expanding research and development efforts in biotechnology. "This
new facility is an investment in America's future, an investment in
New Jersey's economy and an
investment in our nation's intellectual infrastructure."
"We are delighted that Allergan, a multi-specialty health care
company committed to uncovering the best of science, is expanding
its R&D operation here in the heart of New Jersey. With our robust pool of highly
skilled workers in the pharma and biotech sector, New Jersey offers the talent and the location
to help advance medical research," said Congressman Leonard Lance (NJ-07). "Improving our economy is
our number one priority, and Allergan's move - and the jobs it
brings with it - make this a win-win for the company and our
state's residents."
About the R&D Center
In line with Allergan's commitment to the environment and
efforts regarding sustainability issues, the 93,000-square-foot
facility features high-performance, energy-efficient and
environmentally responsible energy systems that produce low
emissions and optimal indoor air quality. The facility was awarded
the U.S. Environmental Protection Agency's prestigious Energy Star
recognition, the national symbol for superior energy efficiency and
environmental protection, and is registered with Leadership in
Energy and Environmental Design (LEED), which is the path to
seeking LEED Existing Building – Operating & Maintenance
certification.
Forward-Looking Statements
This press release contains "forward-looking statements", including
but not limited to the statements by Mr. Pyott, Lt.
Governor Guadagno, Senator Menendez and Congressman Lance.
These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks
or uncertainties materialize, actual results could vary materially
from Allergan's expectations and projections. Risks and
uncertainties include, among other things, general industry and
pharmaceutical market conditions; technological advances and
patents attained by competitors; challenges inherent in the
research and development and regulatory processes; challenges
related to new product marketing, such as the unpredictability of
market acceptance for new pharmaceutical and medical device
products and/or the acceptance of new indications for such
products; inconsistency of treatment results among patients;
potential difficulties in manufacturing; general economic
conditions; and governmental laws and regulations affecting
domestic and foreign operations. Additional information concerning
these and other risk factors can be found in press releases issued
by Allergan, as well as Allergan's public periodic filings with the
U.S. Securities and Exchange Commission, including the discussion
under the heading "Risk Factors" in Allergan's 2011 Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
About Allergan, Inc.
Allergan is a multi-specialty health care company
established more than 60 years ago with a commitment to uncover the
best of science and develop and deliver innovative and meaningful
treatments to help people reach their life's potential. Today, we
have approximately 10,500 highly dedicated and talented employees,
global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of
pharmaceuticals, biologics, medical devices and over-the-counter
consumer products, and state-of-the-art resources in R&D,
manufacturing and safety surveillance that help millions of
patients see more clearly, move more freely and express themselves
more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care,
neurosciences, medical aesthetics, medical dermatology, breast
aesthetics, obesity intervention and urologics, Allergan is proud
to celebrate more than 60 years of medical advances and proud to
support the patients and physicians who rely on our products and
the employees and communities in which we live and work. For more
information regarding Allergan, go to: www.allergan.com.
Allergan Contacts:
Bonnie Jacobs (856)
912-9965 (media)
Cathy Taylor (949) 293-4453
(media)
Jim Hindman (714) 246-4636
(investors)
Joann Bradley (714) 246-4766
(investors)
David Nakasone (714) 246-6376
(investors)
© 2012 Allergan, Inc. Irvine, CA 92612. ® marks owned by
Allergan, Inc. All rights reserved.
SOURCE Allergan, Inc.